The global immunoprecipitation market size was valued at USD 605.0 million in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 5.3% from 2019 to 2026. Growing number of research activities in the life science sector is driving the market. In addition, technological advancements in immunoprecipitation technique is fostering market growth.
Collaborations between researchers and organizations have contributed significantly toward the growth of the life science sector. Scientific innovations by academia in the field of cellular and genetic therapies have led to new techniques for potential biological therapies. Growing number of research activities being conducted in genomics, immunotherapy, and microbiome are widening the scope of new discoveries.
With introduction of modern genetic techniques, there has been continuous growth in R&D for genomics for diseases study, drug development, and designing of personalized treatment. Many regulatory and federal bodies are undertaking strategic initiatives to facilitate genomic research to enhance the healthcare system in their region.
Growing investments in R&D has also driven the market to a large extent. Genomic-based research activities are quite expensive, which generates the need for more investments. GE Healthcare announced an investment of USD 99 million in its protein purification production. Moreover, in 2019, Merck announced its plans to establish a new life science hub focusing on areas such as immunology, oncology, and immuno-oncology.
Technological advancements are significantly evident in immunoprecipitation techniques. Advances in the chromatin immunoprecipitation technique has led to a bead-free method of performing chromatin immunoprecipitation, which is called Chromatrap Immunoprecipitation (ChIP) technology. Epigenetic advancements through ChIP-seq is expected to create high growth opportunities for the market.
Based on product, the market is segmented into kits and reagents. The reagents segment dominated the market in 2018 due to repeated use of various antibodies, beads, and buffers. Agarose beads are widely used by researchers for protein purification methods. However, with the advent of magnetic beads, there has been a steep rise in the demand for the same, thus, driving the market for immunoprecipitation. The kits segment is expected to show significant growth over the forecast period owing to the availability of a wide product portfolio. Some of them are Imprint Chromatin Immunoprecipitation Kit by Merck, Methylated DNA Immunoprecipitation (MeDIP) Kit – DNA by Abcam, and SureBeads Starter Kit by Bio-Rad Laboratories.
The individual protein immunoprecipitation segment held the largest share in the immunoprecipitation market in 2018. This type of immunoprecipitation, where a particular protein is isolated, is most commonly used for protein purification. Co-immunoprecipitation, on the other hand, is associated with protein-protein interactions, wherein it isolates an unknown protein present in a complex solution of the known protein.
Tagged protein IP is anticipated to exhibit lucrative growth over the forecast period. Limitations pertaining to traditional immunoprecipitation techniques have led to the adoption of tagged protein IP. Due to the lack of an available antibody, immunoprecipitation of many proteins might not be possible. Thus, protein can be tagged with an epitope for the purpose of antigen-antibody binding.
Chromatin IP is also exhibiting significant growth due to technological advances. For instance, Chromatrap technology facilitates accuracy in data and provides rapid analysis without any pipetting risks. This allows researchers to analyze multiple antibodies and gene targets simultaneously.
Academic and research institutes is the largest revenue generating segment. This significant share can be attributed to extensive research focused on molecular biology and genomics. The substantial share of this segment is also anticipated to be a consequence of rising government funding for R&D activities. In addition, increasing collaborations between academia and organizations is fostering the growth of this segment.
Contract research organizations (CROs) are expected to exhibit lucrative growth over the forecast period. For higher profit margin, major companies are increasingly outsourcing their research activities as well as drug development activities to CROs. This has significantly broadened the scope for growth of CROs and will continue to do so throughout the forecast period.
North America held the largest revenue share in 2018 due to rise in R&D investments by pharmaceutical and biotechnology companies in the region. In addition, growing life science sector in the U.S. is facilitating high adoption of immunoprecipitation techniques, thus, enhancing protein purification methods. Technological advancements in this region is another factor driving the market.
Asia Pacific is anticipated to register significant growth over the forecast period. Increasing disposable income and infrastructural development in emerging countries such as China and India have led to an increased demand for immunoprecipitation techniques. With growing partnerships and collaborations between universities and organizations, the life science R&D sector is emerging in these markets.
Key manufacturers are engaged in various strategic initiatives such as new product launches, geographic expansion, and mergers and acquisitions. For instance, in 2018, Abbkine introduced Agarose/Magnetic beads Conjugated Tag Antibodies, facilitating a rapid and simple tagged protein immunoprecipitation process.Some of the prominent players in the immunoprecipitation market include:
Thermo Fisher Scientific
Abcam plc
GenScript Biotech Corporation
Merck KGaA
Bio-Rad Laboratories
Takara Bio Inc.
BioLegend
Rockland Immunochemicals Inc.
Abbkine Scientific Co., Ltd.
Cell Signaling Technology, Inc.
Geno Technology Inc.
Report Attribute |
Details |
Market size value in 2020 |
USD 667.2 million |
Revenue forecast in 2026 |
USD 910.0 million |
Growth Rate |
CAGR of 5.3% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, type, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Japan; India; China; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Thermo Fisher Scientific; Abcam plc; GenScript Biotech Corporation; Merck KGaA; Bio-Rad Laboratories; Takara Bio Inc.; BioLegend; Rockland Immunochemicals Inc.; Abbkine Scientific Co., Ltd.; Cell Signaling Technology, Inc.; Geno Technology Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global immunoprecipitation market report on the basis of product, type, end use, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Kits
Reagents
Antibodies
Beads
Others
Type Outlook (Revenue, USD Million, 2015 - 2026)
Individual protein
Protein complex
Chromatin
Ribonucleoprotein
Tagged proteins
End-use Outlook (Revenue, USD Million, 2015 - 2026)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
b. The global immunoprecipitation market size was estimated at USD 635.2 million in 2019 and is expected to reach USD 667.2 million in 2020.
b. The global immunoprecipitation market is expected to grow at a compound annual growth rate of 5.3% from 2019 to 2026 to reach USD 910.0 million by 2026.
b. North America dominated the immunoprecipitation market with a share of 38.3% in 2019. This is attributable to rise in R&D investments by pharmaceutical and biotechnology companies, growing life science sector in the U.S., and technological advancements in this region.
b. Some key players operating in the immunoprecipitation market include Thermo Fisher Scientific; Abcam plc; GenScript Biotech Corporation; Merck KGaA; Bio-Rad Laboratories; Takara Bio Inc.; BioLegend; Rockland Immunochemicals Inc.; Abbkine Scientific Co., Ltd.; Cell Signaling Technology, Inc.; and Geno Technology Inc.
b. Key factors that are driving the market growth include growing number of research activities in the life science, technological advancements in immunoprecipitation technique, and collaborations between researchers and organizations.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.